BioMark Diagnostics Inc

Chart & Performance

D1W1MN

P/E

—

P/S

283.22

EPS

—

Div Yield, %

0.00%

Shrs. gr., 5y

5.28%

Rev. gr., 5y

Revenues

163k

+6.34%

Net income

-1m

L-22.52%

CFO

-983k

L+7.45%

Earnings

Mar 13, 2025

Profile

BioMark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions to detect, monitor, and assess early treatment. It has a collaborative research agreement with the Icahn School of Medicine for clinical studies related to early lung cancer diagnosis. The company was incorporated in 2014 and is headquartered in Richmond, Canada. BioMark Diagnostics Inc. is a subsidiary of Biomark Technologies Inc.

URL

https://www.biomarkdiagnostics.com/

IPO date

Nov 03, 2014

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title CAD in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title CAD in thousands, except ratios and share amounts	2024‑03	2023‑03	2022‑03	2021‑03	2020‑03	2019‑03	2018‑03	2017‑03	2016‑03	2015‑03
Income
Revenues	163 6.34%	153 249.38%	44
Cost of revenue	1,373	2,086	1,362
Unusual Expense (Income)
NOPBT	(1,209)	(1,932)	(1,318)
NOPBT Margin
Operating Taxes			50
Tax Rate
NOPAT	(1,209)	(1,932)	(1,367)
Net income	(1,427) -22.52%	(1,842) 26.71%	(1,454) 32.87%
Dividends
Dividend yield
Proceeds from repurchase of equity	1,542	603	897
BB yield
Debt
Debt current	1,092	1,434	443
Long-term debt	1,260	716	1,415
Deferred revenue
Other long-term liabilities
Net debt	2,192	2,075	1,473
Cash flow
Cash from operating activities	(983)	(914)	(1,204)
CAPEX	(4)	(5)	(59)
Cash from investing activities	(4)	(5)	(59)
Cash from financing activities	1,072	609	768
FCF	(1,587)	(1,996)	(1,751)
Balance
Cash	157	72	383
Long term investments	3	3	3
Excess cash	152	68	384
Stockholders' equity	(3,312)	(3,381)	(2,334)
Invested Capital	4,248	3,873	2,748
ROIC
ROCE
EV
Common stock shares outstanding	85,238	82,778	72,314
Price
Market cap
EV
EBITDA	(816)	(1,546)	(1,138)
EV/EBITDA
Interest	115	110	50
Interest/NOPBT